Beovu injection into the vitreous

Beovu® is indicated for the treatment of neovascular (exudative) age-related macular degeneration (nAMD) in adults.

The efficacy and safety of Beovu® were evaluated in two randomized, multicenter, double-masked, active-controlled Phase III clinical trials, in which 1,817 patients were treated for 2 years (comparator: aflibercept 2 mg). Clinical trial data demonstrated that:

• Beovu® is non-inferior to aflibercept in improving visual acuity;
• Beovu® is more effective than aflibercept in reducing disease activity and anatomical changes, which are key factors in determining injection intervals.

This higher efficacy allows for less frequent dosing (every 12 weeks).

Treatment regimen

For the treatment of nAMD:

• The first three doses of Beovu® are administered as intravitreal injections every 4 weeks.
• Disease activity is assessed 16 weeks after treatment initiation:
  • if the disease is inactive, treatment continues every 12 weeks;
  • if the disease remains active (flare-up phase), treatment is continued every 8 weeks.

Afterward, the physician may individualize the treatment intervals based on the patient’s disease activity.